Corrections to The murky path to drug discovery in ALS becomes clearer [Lancet Neurol, 12, (2013) 1037-38]

摘要

Gordon PH. The murky path to drug discovery in AL5 becomes dearer. Lancet Neurol 2013; 12:1037-38-The sentence "Some researchers contend that the standard parallel-arm phase 2 trial seeking evidence of efficacy gives erroneous outcomes in ALS, but history shows that the standard parallel-arm phase 2 trial shows erroneous outcomes in ALS" has been replaced with "Some researchers contend that a low threshold for declaring non-futility is susceptible to error, but history shows that it is the standard parallel phase 2 trial that demonstrates erroneous efficacy outcomes in ALS" This correction has been made to the online version as of Nov 11, 2013